Finance

Lists
Q3 2026 earnings • released • EPS beat +13.60%
See results
PYXS:NASDAQ
Pyxis Oncology Inc
$1.66
0.00%
(0.00) 1D
Nov 6, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PYXS...
Mkt. cap
198.51M
Avg. vol.
1.19M
Volume
1.08K
52-wk high
$5.55
52-wk low
$1.03
EPS
-$1.40
Beta
1.41
Shares outstanding
119.61M
No. of employees
56
Mkt. cap
198.51M
Avg. vol.
1.19M
Volume
1.08K
52-wk high
$5.55
52-wk low
$1.03
EPS
-$1.40
Beta
1.41
Shares outstanding
119.61M
No. of employees
56
News stories
From web sources and news partners
About Pyxis Oncology Inc
CEO-
Employees56
Founded2018
HeadquartersBoston, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Websitepyxisoncology.com
Analyst ratings
Based on 8 analysts giving stock ratings to PYXS in the past 3 months
Strong buy
Buy
7
Hold
1
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for PYXS in the last 3 months.
Highest
Current $1.66
$19.00 (+1,044.58%)
Average
$8.71 (+424.70%)
Lowest
$5.00 (+201.20%)
Analyst
Recommendation
Action
Price target
Projected
Date
Swayampakula Ramakanth
H.C. Wainwright
Buy
Reiterated
$8.00
+381.9%
11/09/2026
Robert Driscoll
Wedbush
Buy
Reiterated
$7.00
+321.7%
11/06/2026
Leonid Timashev
RBC Capital
Buy
Reiterated
$7.00
+321.7%
11/06/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$7.00
+321.7%
11/05/2026
Stephen Willey
Stifel Nicolaus
Buy
Reiterated
$5.00
+201.2%
11/06/2026
Derek Archila
Wells Fargo
Buy
Reiterated
$19.00
+1,044.6%
10/16/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$8.00
+381.9%
09/26/2026
Andy Hsieh
William Blair
Hold
Reiterated
-
-
09/09/2026
Alexandra Ramsey
William Blair
Hold
Reiterated
-
-
09/09/2026
Last report
Nov 5, 2026
Fiscal period
Q3 2026
-$0.24 / -$0.28
+13.60%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
11.04M
-
-
-
Cost of goods sold
2.39M
-
-
-
Cost of revenue
2.39M
-
-
-
Research and development expenses
21.71M
19.98M
16.06M
16.56M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.54M
3.75M
9.54M
3.97M
Operating expense
26.25M
23.73M
25.60M
20.52M
Total operating expenses
28.64M
23.73M
25.60M
20.52M
Operating income
-17.60M
-23.73M
-25.60M
-20.52M
Other non operating income
-
-
-
-
EBT including unusual items
-17.00M
-23.27M
-25.35M
-19.98M
EBT excluding unusual items
-17.00M
-23.27M
-25.35M
-19.98M
Income tax expense
1.10M
-
-
-
Effective tax rate
-6.49%
-
-
-
Other operating expenses
-
-
-
-
Net income
-18.11M
-23.27M
-25.35M
-19.98M
Net profit margin
-164.03%
-
-
-
Earnings per share
-0.29
-0.37
-0.40
-0.24
Interest and investment income
600.00K
457.00K
255.00K
539.00K
Interest expense
-
-
-
-
Net interest expenses
600.00K
457.00K
255.00K
539.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-14.71M
-23.27M
-25.30M
-20.22M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps